The Impact of Multidisciplinary Team Meetings on Patient Management in Oncologic Thoracic Surgery: A Single-Center Experience.
multidisciplinary team meeting
thoracic oncology
tumor boards
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jan 2021
10 Jan 2021
Historique:
received:
21
12
2020
revised:
05
01
2021
accepted:
08
01
2021
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
14
1
2021
Statut:
epublish
Résumé
the aim of this paper is to quantify multidisciplinary team meeting (MDT) impact on the decisional clinical pathway of thoracic cancer patients, assessing the modification rate of the initial out-patient evaluation. the impact of MDT was classified as follows: confirmation: same conclusions as out-patient hypothesis; modification: change of out-patient hypothesis; implementation: definition of a clear clinical track/conclusion for patients that did not receive any clinical hypothesis; further exams required: the findings that emerged in the MDT meeting require further exams. one thousand consecutive patients evaluated at MDT meetings were enrolled. Clinical settings of patients were: early stage lung cancer (17.4%); locally advanced lung cancer (27.4%); stage IV lung cancer (9.8%); mesothelioma (1%); metastases to the lung from other primary tumors (4%); histologically proven or suspected recurrence from previous lung cancer (15%); solitary pulmonary nodule (19.2%); mediastinal tumors (3.4%); other settings (2.8%). MDT meetings impact patient management in oncologic thoracic surgery by modifying the out-patient clinical hypothesis in 10.6% of cases; the clinical settings with the highest decisional modification rates are "solitary pulmonary nodule" and "proven or suspected recurrence" with modification rates of 14.6% and 13.3%, respectively.
Sections du résumé
BACKGROUND
BACKGROUND
the aim of this paper is to quantify multidisciplinary team meeting (MDT) impact on the decisional clinical pathway of thoracic cancer patients, assessing the modification rate of the initial out-patient evaluation.
METHODS
METHODS
the impact of MDT was classified as follows: confirmation: same conclusions as out-patient hypothesis; modification: change of out-patient hypothesis; implementation: definition of a clear clinical track/conclusion for patients that did not receive any clinical hypothesis; further exams required: the findings that emerged in the MDT meeting require further exams.
RESULTS
RESULTS
one thousand consecutive patients evaluated at MDT meetings were enrolled. Clinical settings of patients were: early stage lung cancer (17.4%); locally advanced lung cancer (27.4%); stage IV lung cancer (9.8%); mesothelioma (1%); metastases to the lung from other primary tumors (4%); histologically proven or suspected recurrence from previous lung cancer (15%); solitary pulmonary nodule (19.2%); mediastinal tumors (3.4%); other settings (2.8%).
CONCLUSIONS
CONCLUSIONS
MDT meetings impact patient management in oncologic thoracic surgery by modifying the out-patient clinical hypothesis in 10.6% of cases; the clinical settings with the highest decisional modification rates are "solitary pulmonary nodule" and "proven or suspected recurrence" with modification rates of 14.6% and 13.3%, respectively.
Identifiants
pubmed: 33435181
pii: cancers13020228
doi: 10.3390/cancers13020228
pmc: PMC7827504
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Ministry of Health "5x1000" + European Institute of Oncology Foundation
ID : no number
Références
Interact Cardiovasc Thorac Surg. 2002 Dec;1(2):78-80
pubmed: 17669965
Asia Pac J Clin Oncol. 2019 Aug;15(4):199-207
pubmed: 31115170
JTO Clin Res Rep. 2020 Nov 1;1(4):100073
pubmed: 33225316
Transl Lung Cancer Res. 2020 Aug;9(4):1654-1666
pubmed: 32953539
Int J Surg Pathol. 2006 Jul;14(3):247-51
pubmed: 16959714
BMC Cancer. 2020 Oct 8;20(1):974
pubmed: 33032547
Cancer. 2011 Nov 15;117(22):5112-20
pubmed: 21523766
Eur J Radiol Open. 2020 Dec 01;7:100291
pubmed: 33304940
Intern Med J. 2007 Jan;37(1):18-25
pubmed: 17199840
Cancer. 2006 Nov 15;107(10):2346-51
pubmed: 16998942
Ann R Coll Surg Engl. 2021 Jan;103(1):10-17
pubmed: 32981347
Clin Nucl Med. 2003 Jul;28(7):548-52
pubmed: 12819406
Cancer Treat Rev. 2016 Jan;42:56-72
pubmed: 26643552
Lung Cancer. 2004 Nov;46(2):227-32
pubmed: 15474671
Semin Thorac Cardiovasc Surg. 2017 Summer;29(2):233-241
pubmed: 28823336
J Cancer Educ. 2008;23(4):235-7
pubmed: 19058072
Thorax. 1998 Jun;53 Suppl 1:S1-8
pubmed: 9713437
Transl Lung Cancer Res. 2018 Feb;7(1):88-102
pubmed: 29535915
Otolaryngol Head Neck Surg. 2010 Nov;143(5):650-4
pubmed: 20974334
Chest. 2003 Jan;123(1 Suppl):D-G, 1S-337S
pubmed: 12527560
Respirology. 2015 Feb;20(2):192-8
pubmed: 25581058
Asia Pac J Clin Oncol. 2016 Jun;12(2):e298-304
pubmed: 24674013
Biology (Basel). 2020 Dec 25;10(1):
pubmed: 33375573
Br J Cancer. 2005 Oct 31;93(9):977-8
pubmed: 16234818
Lung Cancer. 2018 Oct;124:199-204
pubmed: 30268461
Respirology. 2018 Oct;23(10):927-934
pubmed: 29641841
Eur J Cardiothorac Surg. 2009 May;35(5):792-6
pubmed: 19233682
Eur J Cardiothorac Surg. 2020 Jun 1;57(6):1173-1180
pubmed: 32091083
J Pediatr Hematol Oncol. 2021 Aug 1;43(6):e873-e879
pubmed: 33003143
J Oncol Pract. 2005 Sep;1(3):84-92
pubmed: 20871689
Int J Surg. 2005;3(2):121-3
pubmed: 17462272
J Med Vasc. 2020 Nov;45(6S):6S24-6S30
pubmed: 33276940
Cancer. 2021 Jul 15;127(14):2579-2586
pubmed: 33237591
Diagnostics (Basel). 2017 Oct 17;7(4):
pubmed: 29039744
BMC Health Serv Res. 2020 Jan 31;20(1):73
pubmed: 32005232
Surgeon. 2011 Apr;9(2):72-7
pubmed: 21342670
Transl Lung Cancer Res. 2020 Aug;9(4):1422-1432
pubmed: 32953514
Lung Cancer. 2003 Dec;42(3):283-90
pubmed: 14644515
Int J Gynecol Cancer. 2010 Nov;20(8):1321-5
pubmed: 21051971
Clin Lung Cancer. 2018 Jul;19(4):346-351
pubmed: 29506890
Lung Cancer. 2008 Apr;60(1):14-21
pubmed: 18304687
Ann Thorac Surg. 2014 Feb;97(2):480-3
pubmed: 24370201
J Natl Cancer Inst Monogr. 2010;2010(40):72-80
pubmed: 20386055
Urol Oncol. 2011 Jul-Aug;29(4):378-82
pubmed: 19576797